All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract| Pooled allogeneic faecal microbiota therapy for steroid resistant GI-aGvHD

Sep 19, 2023
Learning objective: After reading this article, learners will be able to discuss the efficacy and safety of pooled allogeneic faecal microbiota transplant for the treatment of steroid-refractory GI-aGvHD.

Bookmark this article

Severe gastrointestinal acute graft versus host disease (GI-aGvHD) is a serious complication that can occur after allogeneic hematopoietic cell transplantation (allo-HCT). Gut dysbiosis and a loss of bacterial diversity in the intestinal microbiome post-transplantation is thought to be an important factor in the development of the condition.

Fecal microbiota transplant is currently under investigation for the treatment of GI-aGvHD, with several pilot studies highlighting encouraging data. While the issue of donor sourcing remains a problem for fecal microbiota transplantation, one potential solution has been the development of a standardized fecal microbiota transplant product, MaaT013. This new form of microbiota therapy has previously been reported on the GvHD Hub.

Recently, Malard et al. performed the multicenter, single arm phase II HERACLES study (NCT03359980) investigating the safety and efficacy of MaaT013 in patients diagnosed with steroid-refractory GI-aGvHD. Here, we summarize the key results.

Visual Abstract

To download this visual abstract, click below.

Download here


Subscribe to get the best content related to GvHD delivered to your inbox